Chloramphenicol pharmacokinetics in infants less than three months of age in the Philippines and The Gambia

被引:5
|
作者
Weber, MW [1 ]
Gatchalian, SR
Ogunlesi, O
Smith, A
McCracken, GH
Qazi, S
Weber, AF
Olsen, K
Mulholland, EK
机构
[1] WHO, CAH, CH-1211 Geneva 27, Switzerland
[2] Med Res Council Labs, Fajara, Gambia
[3] Res Inst Trop Med, Metro Manila, Manila, Philippines
[4] Univ Texas, SW Med Ctr, Dallas, TX USA
关键词
chloramphenicol; developing countries; pneumonia; meningitis; child;
D O I
10.1097/00006454-199910000-00012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The broad antimicrobial spectrum and affordable price of chloramphenicol make it an attractive first line treatment option for children with severe illnesses in developing countries. Little is known, however, about its pharmacokinetics in young infants in these settings. Methods. We studied infants younger than 3 months of age hospitalized in Manila, Philippines and The Gambia with possible severe bacterial infections likely to benefit from treatment with chloramphenicol. Infants in the first week of life received intramuscular doses of 25 mg/kg chloramphenicol once daily, twice daily in the second through fourth week of life and three times daily from 5 to 12 weeks of age. Blood samples There taken at 0.5, 1, 2 and 3 h after the first dose, 1 h before the second dose and before the repetition doses on subsequent days. In the Philippines a second group of infants was treated with oral chloramphenicol according to the same dosage schedule. Results. Thirty-eight infants received intramuscular chloramphenicol, and 20 received oral drug. Intramuscular administration resulted in therapeutic concentrations (10 to 25 mu g/ml) in 73 to 86% of children in each of the three age groups in the first 6 h and in 50 to 80% on Days 2 and 3. Between 33 and 38% of children had potentially toxic values on Days 2 and 3. In contrast, after oral administration, only about one-half of the children reached therapeutic values in serum at any time up to Day 3 after start of treatment. Conclusions. Intramuscular chloramphenicol can be used as a second line drug for the treatment of severe infections in infants younger than 90 days of age, where third generation cephalosporins are not available. It quickly achieves therapeutic values in a high proportion of children. However, severe infections should not be treated with oral chloramphenicol in this age group, because therapeutic serum concentrations were inconsistently achieved.
引用
收藏
页码:896 / 901
页数:6
相关论文
共 50 条
  • [1] Population Pharmacokinetics of Ciprofloxacin in Neonates and Young Infants Less than Three Months of Age
    Zhao, W.
    Hill, H.
    Le Guellec, C.
    Neal, T.
    Mahoney, S.
    Paulus, S.
    Castellan, C.
    Kassai, B.
    Van den Anker, J. N.
    Kearns, G. L.
    Turner, M. A.
    Jacqz-Aigrain, E.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 22 - 22
  • [2] Population Pharmacokinetics of Ciprofloxacin in Neonates and Young Infants Less than Three Months of Age
    Zhao, Wei
    Hill, Helen
    Le Guellec, Chantal
    Neal, Tim
    Mahoney, Sarah
    Paulus, Stephane
    Castellan, Charlotte
    Kassai, Behrouz
    van den Anker, Johannes N.
    Kearns, Gregory L.
    Turner, Mark A.
    Jacqz-Aigrain, Evelyne
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6572 - 6580
  • [3] Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age
    Saez-Llorens, Xavier
    Macias, Mercedes
    Maiya, Padmanabha
    Pineros, Juan
    Jafri, Hasan S.
    Chatterjee, Archana
    Ruiz, Gloria
    Raghavan, Janaki
    Bradshaw, Susan K.
    Kartsonis, Nicholas A.
    Sun, Peng
    Strohmaier, Kim M.
    Fallon, Marissa
    Bi, Sheng
    Stone, Julie A.
    Chow, Joseph W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) : 869 - 875
  • [4] Influenza Virus Infection in Infants Less Than Three Months of Age
    Bender, Jeffrey M.
    Ampofo, Krow
    Gesteland, Per
    Sheng, Xiaoming
    Korgenski, Kent
    Raines, Bill
    Daly, Judy A.
    Valentine, Karen
    Srivastava, Rajendu
    Pavia, Andrew T.
    Byington, Carrie L.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (01) : 6 - 9
  • [5] HEMATOCHEZIA IN INFANTS LESS THAN 6 MONTHS OF AGE
    SILBER, GH
    KLISH, WJ
    [J]. AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1986, 140 (11): : 1097 - 1098
  • [6] Tuberculosis in infants less than 3 months of age
    del Rosal Rabes, Teresa
    Baquero-Artigao, Fernando
    Maria Mendez-Echevarria, Ana
    Mellado Pena, Maria Jose
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2017, 35 (04): : 243 - 245
  • [7] Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age
    Chalkiadis, GA
    Anderson, BJ
    Tay, M
    Bjorksten, A
    Kelly, JJ
    [J]. BRITISH JOURNAL OF ANAESTHESIA, 2005, 95 (04) : 524 - 529
  • [8] POPULATION PHARMACOKINETICS OF CIPROFLOXACIN AND DOSING RECOMMENDATION IN NEONATES AND INFANTS LESS THAN 3 MONTHS OF AGE.
    Barin-Le Guellec, C.
    Zhao, W.
    Kassai, B.
    Turner, M. A.
    Jacqz-Aigrain, E.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S77 - S77
  • [9] TUBERCULOSIS IN INFANTS LESS-THAN 3 MONTHS OF AGE
    SCHAAF, HS
    GIE, RP
    BEYERS, N
    SMUTS, N
    DONALD, PR
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 1993, 69 (03) : 371 - 374
  • [10] Cochlear implantation in infants less than 12 months of age
    Valencia, David M.
    Rimell, Frank L.
    Friedman, Barbara J.
    Oblander, Melisa R.
    Helmbrecht, Josephine
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2008, 72 (06) : 767 - 773